Sagent CEO: China Plant Producing, First Quarter Looks "Strong"

Earnings visibility is difficult due to the multi-faceted nature of Sagent's generic drug business, however, CEO Jeffrey Yordon says he anticipates a strong first quarter after seeing sales rise 20% in Q4. He expects Sagent to launch between 12 and 16 new products this year after launching a dozen last year. Yordon also says the company's new Chinese plant is already FDA-approved and manufacturing products, and he has high expectations for Sagent's research center in Chengdu China.